Newbridge Financial Services Group’s Akero Therapeutics AKRO Stock Holding History

Newbridge Financial Services Group’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-65	Closed	-$3.29K	–	1131
2023 Q3	$3.29K	Hold	65	–	–	﹤0.01%	1015
2023 Q2	$3.04K	Hold	65	–	–	﹤0.01%	1086
2023 Q1	$2.49K	Hold	65	–	–	﹤0.01%	1169
2022 Q4	$3.56K	Hold	65	–	–	﹤0.01%	1125
2022 Q3	$2K	Hold	65	–	–	﹤0.01%	1171
2022 Q2	$1K	Hold	65	–	–	﹤0.01%	1246
2022 Q1	$1K	Hold	65	–	–	﹤0.01%	1354
2021 Q4	$1K	Hold	65	–	–	﹤0.01%	1297
2021 Q3	$1K	Hold	65	–	–	﹤0.01%	1215
2021 Q2	$2K	Hold	65	–	–	﹤0.01%	1252
2021 Q1	$2K	Buy	+65	New	+$1.97K	﹤0.01%	1151

Other funds holding AKRO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Newbridge Financial Services Group's AKRO Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 65 shares — an estimated $3.29K sold.

Newbridge Financial Services Group first reported a position in AKRO in Q1 2021 and held it in 11 quarters. The position peaked at $3.56K in Q4 2022. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

Newbridge Financial Services Group reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
Newbridge Financial Services Group sold 65 Akero Therapeutics shares in Q4 2023, an estimated $3.29K.
Newbridge Financial Services Group first reported a position in Akero Therapeutics in Q1 2021 and held it in 11 quarters.
Newbridge Financial Services Group's Akero Therapeutics position peaked at $3.56K in Q4 2022.
157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.